Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Adv TherJun 30, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Franziska Dirnberger, Sachin Patel, Devon J Boyne et al.

✦ AI-curated · Sources linked

In 30 seconds

This study conducted a matching-adjusted indirect comparison of tarlatamab versus paclitaxel and CAV in patients with platinum-refractory or platinum-resistant extensive-stage small-cell lung cancer (ES-SCLC). The analysis revealed that tarlatamab was associated with longer overall survival compared to paclitaxel (HR 0.35) and CAV (HR 0.48), suggesting a potential benefit in this patient population.

Key findings

  • Tarlatamab showed longer overall survival compared to paclitaxel (HR 0.35, p < 0.001).
  • Tarlatamab also demonstrated longer overall survival compared to CAV (HR 0.48, p < 0.001).
  • Tarlatamab improved progression-free survival, overall response rate, and disease control rate relative to paclitaxel (p < 0.05).
  • No significant differences were found between tarlatamab and CAV regarding PFS, ORR, or DCR (p > 0.05).

Why it matters

The findings indicate that tarlatamab may offer improved survival outcomes for patients with limited treatment options due to platinum-refractory or platinum-resistant ES-SCLC, highlighting the need for effective second-line therapies in this aggressive cancer.

What to keep in mind

These findings are subject to residual confounding and should be interpreted with caution.

Source

PubMed · PMID 42377743Free full text on PubMed Central

Published in Adv Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.